Sodium Pentaborate

Phase 2Small molecule

Sodium Pentaborate is one of 80 small molecule programs targeting Postmenopausal Osteoporosis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal OsteoporosisActive, not recruiting

Renal Cell CarcinomaActive, not recruiting

Postmenopausal OsteoporosisPhase 2

Active, not recruiting

Renal Cell CarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

363 competitors in Renal Cell Carcinoma

#DrugCompanyPhaseTrials

Cabometyx

Bristol-Myers Squibb

Phase 3

31 2

Votrient

Novartis

Phase 3

25 3

Nexavar

Bayer

Phase 3

23 4

Lenvima

Eisai

Phase 3

21 5

Tecentriq

Roche

Phase 3

8 6

Welireg

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

18 7

Imjudo

AstraZeneca

Phase 3

3 8

Imfinzi

AstraZeneca

Phase 3

2 9

TKI258

Novartis

Phase 3

1 10

Roferon-a

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Efficacy of OsteoBor in Postmenopausal Osteoporosis

Not yet recruiting·TTabriz University of Medical Sciences·Phase 2·NCT06809816·30 enrolled

Mild to Moderate Alzheimer's Disease1 trial

The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease

Not yet recruiting·TTabriz University of Medical Sciences·Phase 2·NCT06840054·30 enrolled

Overweight1 trial

Safety and Efficacy of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity

Unknown status·TTabriz University of Medical Sciences·Phase 1/2·NCT05741606·120 enrolled

Renal Cell Carcinoma1 trial

Evaluation of the Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Advanced Renal Cell Carcinoma

Not yet recruiting·TTabriz University of Medical Sciences·Phase 1/2·NCT05798455·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Sodium Pentaborate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sodium Pentaborate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sodium Pentaborate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tabriz University of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTabriz University of Medical Sciences

Sodium Pentaborate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Postmenopausal Osteoporosis1 trial

Mild to Moderate Alzheimer's Disease1 trial

Overweight1 trial

Renal Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News